LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 71

Search options

  1. Article ; Online: A quantum leap in cancer vaccines?

    Gilboa, Eli

    Journal for immunotherapy of cancer

    2016  Volume 4, Page(s) 87

    Language English
    Publishing date 2016
    Publishing country England
    Document type Editorial
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1186/s40425-016-0192-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Vaccination against neoantigens induced in cross-priming cDC1 in vivo.

    Clark, Emily S / Benaduce, Ana Paula / Khan, Wasif N / Martinez, Olivier / Gilboa, Eli

    Cancer immunology, immunotherapy : CII

    2024  Volume 73, Issue 1, Page(s) 9

    Abstract: The conventional type 1 dendritic cells (cDC1) play a pivotal role in protective immunity against pathogens and cancer. However, their low frequency in the blood and tissues limits their use in immune therapy. We have recently described a method to ... ...

    Abstract The conventional type 1 dendritic cells (cDC1) play a pivotal role in protective immunity against pathogens and cancer. However, their low frequency in the blood and tissues limits their use in immune therapy. We have recently described a method to vaccinate against neoantigens that are induced in tumor cells by targeted delivery of a TAP siRNA to dendritic cells using a TLR9 binding CpG oligonucleotide. Since TLR9 is also expressed in immune suppressive myeloid populations TLR9 targeting could reduce the effectiveness of this approach. Here, we describe a modular multivalent antibody platform to target the TAP siRNA to resident Clec9a expressing cDC1 and show that it leads to selective and sustained TAP downregulation in cDC1 and inhibits tumor growth in mice more effectively than CpG targeted siRNA. To induce DC maturation an agonistic CD40 antibody was administered to the siRNA treated mice. To obviate the need for a second drug formulation and reduce the risk of toxicity, we exploited the multivalent nature of this targeting platform to co-deliver the TAP siRNA and a DC maturation agent, a CpG containing oligonucleotide, to cDC1 in vivo and show that it was more effective than Clec9a targeting of TAP siRNA in combination with CD40 antibody. This study describes a way to manipulate the function of cDC1 cells in vivo using a broadly applicable antibody-based targeting platform to deliver multiple biological agents to specific cells in vivo to potentiate (immune) therapy and to probe the biology of specific cell types in their natural settings.
    MeSH term(s) Animals ; Mice ; Cross-Priming ; Toll-Like Receptor 9 ; Antibodies ; Vaccination ; RNA, Small Interfering/genetics ; CD40 Antigens ; Oligonucleotides
    Chemical Substances Toll-Like Receptor 9 ; Antibodies ; RNA, Small Interfering ; CD40 Antigens ; Oligonucleotides
    Language English
    Publishing date 2024-01-17
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 195342-4
    ISSN 1432-0851 ; 0340-7004
    ISSN (online) 1432-0851
    ISSN 0340-7004
    DOI 10.1007/s00262-023-03597-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1237: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The Quest for mRNA Vaccines.

    Gilboa, Eli / Boczkowski, David / Nair, Smita K

    Nucleic acid therapeutics

    2022  Volume 32, Issue 6, Page(s) 449–456

    Abstract: The success of mRNA vaccines against COVID-19 is nothing short of a medical revolution. Given its chemical lability the use of mRNA as a therapeutic has been counterintuitive and met with skepticism. The development of mRNA-based COVID-19 vaccines was ... ...

    Abstract The success of mRNA vaccines against COVID-19 is nothing short of a medical revolution. Given its chemical lability the use of mRNA as a therapeutic has been counterintuitive and met with skepticism. The development of mRNA-based COVID-19 vaccines was the culmination of long and painstaking efforts by many investigators spanning over 30 years and culminating with the seminal studies of Kariko and Weissman. This review will describe one chapter in this saga, studies that have shown that mRNA can function as a therapeutic. It started with our seminal observation that dendritic cells (DCs) transfected with mRNA
    MeSH term(s) Humans ; Animals ; Mice ; COVID-19 Vaccines/genetics ; COVID-19/prevention & control ; mRNA Vaccines
    Chemical Substances COVID-19 Vaccines ; mRNA Vaccines
    Language English
    Publishing date 2022-11-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2639888-6
    ISSN 2159-3345 ; 2159-3337
    ISSN (online) 2159-3345
    ISSN 2159-3337
    DOI 10.1089/nat.2021.0103
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay.

    Gilboa, Eli

    Immunologic research

    2013  Volume 57, Issue 1-3, Page(s) 44–51

    Abstract: The main reason why tumors are not controlled by the immune system of the cancer patient is that tumors do not express potent tumor antigens that can be recognized by the immune system as "foreign." The current focus in developing immune-based modalities ...

    Abstract The main reason why tumors are not controlled by the immune system of the cancer patient is that tumors do not express potent tumor antigens that can be recognized by the immune system as "foreign." The current focus in developing immune-based modalities is to potentiate an immune response against the existing, albeit weak, antigens expressed in the tumor. An alternative approach is to express new, and hence potent, antigens in tumor cells in situ. To this end, we have developed an approach to generate new antigenic determinants in tumor cells using siRNA technology to inhibit nonsense-mediated mRNA decay (NMD), a surveillance mechanism which prevents the expression of mRNAs containing a premature termination codon. Targeting siRNA inhibition to tumor cells--an essential requisite because of the constitutive nature and physiological roles of the NMD process--is accomplished by using a novel targeting technology based on using oligonucleotide aptamer ligands. Aptamers or aptamer-targeted siRNA conjugates, unlike antibodies, can be synthesized in a chemical process providing a more straightforward and cost-effective manufacturing and regulatory approval process to generate clinical-grade reagents. In murine tumor models, the aptamer-targeted siRNA-mediated NMD inhibition in tumor cells led to significant inhibition of tumor growth, which was superior to best-in-class "conventional" cancer vaccination protocols. Tumor-targeted NMD inhibition forms the basis of a simple, broadly useful, and clinically feasible approach to enhance the antigenicity of disseminated tumors leading to their immune recognition and rejection. The cell-free chemically synthesized oligonucleotide backbone of aptamer-siRNAs reduces the risk of immunogenicity and enhances the feasibility of generating reagents suitable for clinical use.
    MeSH term(s) Animals ; Antigens, Neoplasm/genetics ; Antigens, Neoplasm/immunology ; Aptamers, Nucleotide/genetics ; Aptamers, Nucleotide/metabolism ; Disease Models, Animal ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/therapy ; Nonsense Mediated mRNA Decay
    Chemical Substances Antigens, Neoplasm ; Aptamers, Nucleotide
    Language English
    Publishing date 2013-11-05
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 632857-x
    ISSN 1559-0755 ; 0257-277X
    ISSN (online) 1559-0755
    ISSN 0257-277X
    DOI 10.1007/s12026-013-8442-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1755: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: mRNA leapfrogs DNA to show promise for therapeutic gene transfer.

    Gilboa, Eli

    Molecular therapy : the journal of the American Society of Gene Therapy

    2012  Volume 20, Issue 4, Page(s) 694–695

    MeSH term(s) Animals ; Erythropoiesis/drug effects ; Erythropoietin/genetics ; Female ; Humans ; Pseudouridine/genetics ; RNA, Messenger
    Chemical Substances RNA, Messenger ; Erythropoietin (11096-26-7) ; Pseudouridine (1445-07-4)
    Language English
    Publishing date 2012-04-03
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2010592-7
    ISSN 1525-0024 ; 1525-0016
    ISSN (online) 1525-0024
    ISSN 1525-0016
    DOI 10.1038/mt.2012.31
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5640: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment.

    Wei, Jun / Gilboa, Eli / Calin, George A / Heimberger, Amy B

    Frontiers in oncology

    2021  Volume 11, Page(s) 682129

    Abstract: Glioblastomas are heterogeneous and have a poor prognosis. Glioblastoma cells interact with their neighbors to form a tumor-permissive and immunosuppressive microenvironment. Short noncoding RNAs are relevant mediators of the dynamic crosstalk among ... ...

    Abstract Glioblastomas are heterogeneous and have a poor prognosis. Glioblastoma cells interact with their neighbors to form a tumor-permissive and immunosuppressive microenvironment. Short noncoding RNAs are relevant mediators of the dynamic crosstalk among cancer, stromal, and immune cells in establishing the glioblastoma microenvironment. In addition to the ease of combinatorial strategies that are capable of multimodal modulation for both reversing immune suppression and enhancing antitumor immunity, their small size provides an opportunity to overcome the limitations of blood-brain-barrier (BBB) permeability. To enhance glioblastoma delivery, these RNAs have been conjugated with various molecules or packed within delivery vehicles for enhanced tissue-specific delivery and increased payload. Here, we focus on the role of RNA therapeutics by appraising which types of nucleotides are most effective in immune modulation, lead therapeutic candidates, and clarify how to optimize delivery of the therapeutic RNAs and their conjugates specifically to the glioblastoma microenvironment.
    Language English
    Publishing date 2021-08-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.682129
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: DC-based cancer vaccines.

    Gilboa, Eli

    The Journal of clinical investigation

    2007  Volume 117, Issue 5, Page(s) 1195–1203

    Abstract: Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful vaccination protocols. An approach gaining ... ...

    Abstract Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful vaccination protocols. An approach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with their own DCs loaded ex vivo with tumor antigens. The underlying premise of this approach is that the efficiency and control over the vaccination process provided by ex vivo manipulation of the DCs generates an optimally potent APC and a superior method for stimulating antitumor immunity in vivo compared with the more conventional direct vaccination methods, offsetting the added cost and complexity associated with this form of customized cell therapy.
    MeSH term(s) Animals ; Antigens, Neoplasm/administration & dosage ; Antigens, Neoplasm/therapeutic use ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Dendritic Cells/immunology ; Dendritic Cells/transplantation ; Humans ; Immunotherapy, Adoptive/methods ; Neoplasms/immunology ; Neoplasms/prevention & control
    Chemical Substances Antigens, Neoplasm ; Cancer Vaccines
    Language English
    Publishing date 2007-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI31205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Knocking the SOCS1 off dendritic cells.

    Gilboa, Eli

    Nature biotechnology

    2004  Volume 22, Issue 12, Page(s) 1521–1522

    MeSH term(s) Animals ; Antigen Presentation/genetics ; Antigen Presentation/immunology ; Carrier Proteins/genetics ; Carrier Proteins/metabolism ; Cell Differentiation ; Cell Line, Tumor ; Dendritic Cells/cytology ; Dendritic Cells/immunology ; Dendritic Cells/transplantation ; Gene Silencing/immunology ; Immunotherapy, Adoptive/methods ; Melanoma/immunology ; Melanoma/pathology ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Suppressor of Cytokine Signaling 1 Protein ; Suppressor of Cytokine Signaling Proteins
    Chemical Substances Carrier Proteins ; Repressor Proteins ; Socs1 protein, mouse ; Suppressor of Cytokine Signaling 1 Protein ; Suppressor of Cytokine Signaling Proteins
    Language English
    Publishing date 2004-12
    Publishing country United States
    Document type News ; Comment
    ZDB-ID 1311932-1
    ISSN 1546-1696 ; 1087-0156
    ISSN (online) 1546-1696
    ISSN 1087-0156
    DOI 10.1038/nbt1204-1521
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2167: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 137: Show issues
    Zs.MG 43: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: The promise of cancer vaccines.

    Gilboa, Eli

    Nature reviews. Cancer

    2004  Volume 4, Issue 5, Page(s) 401–411

    MeSH term(s) Animals ; Cancer Vaccines/therapeutic use ; Humans ; Neoplasms/immunology ; Neoplasms/prevention & control
    Chemical Substances Cancer Vaccines
    Language English
    Publishing date 2004
    Publishing country England
    Document type Review
    ZDB-ID 2062767-1
    ISSN 1474-1768 ; 1474-175X
    ISSN (online) 1474-1768
    ISSN 1474-175X
    DOI 10.1038/nrc1359
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5563: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 24: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.

    Schrand, Brett / Clark, Emily / Levay, Agata / Capote, Ailem Rabasa / Martinez, Olivier / Brenneman, Randall / Castro, Iris / Gilboa, Eli

    Nature communications

    2021  Volume 12, Issue 1, Page(s) 6939

    Language English
    Publishing date 2021-11-22
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-021-25400-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top